CytoCore Inc. (MDIT) Director William Austin Iv Lewis Purchases 10,666,667 Shares

CytoCore Inc. (OTCMKTS:MDIT) Director William Austin Iv Lewis bought 10,666,667 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was bought at an average price of $0.08 per share, for a total transaction of $853,333.36. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

CytoCore Inc. (MDIT) remained flat at $$0.19 on Monday. 6,068 shares of the stock were exchanged, compared to its average volume of 10,072. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 0.69. The stock has a market capitalization of $5.34, a PE ratio of -0.88 and a beta of -2.38. CytoCore Inc. has a 52 week low of $0.11 and a 52 week high of $0.88.

CytoCore (OTCMKTS:MDIT) last released its earnings results on Tuesday, November 14th. The company reported ($0.06) earnings per share for the quarter. CytoCore had a negative net margin of 76.67% and a negative return on equity of 71.60%.

Separately, ValuEngine upgraded shares of CytoCore from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at

About CytoCore

MEDITE Cancer Diagnostics, Inc (MEDITE), formerly CytoCore, Inc, is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases.

Receive News & Ratings for CytoCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoCore and related companies with's FREE daily email newsletter.

Leave a Reply